PTC Therapeutics (NASDAQ: PTCT) — Company Overview, News & Financial Data
PTC Therapeutics is a biopharmaceutical company focused on novel therapies for rare genetic disorders and critical illnesses.
PTC Therapeutics
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule oral therapeutics and gene therapies for rare genetic disorders and diseases with high unmet medical need. Its commercial and clinical pipeline targets severe conditions including Duchenne muscular dystrophy, spinal muscular atrophy, aromatic L-amino acid decarboxylase deficiency, phenylketonuria, Friedreich's ataxia, and Huntington's disease. The company utilizes proprietary RNA-splicing modification and ferroptosis regulation technology platforms to develop targeted disease-modifying treatments. Operations span research, clinical trial management, regulatory compliance, and commercial marketing across North America, Europe, Latin America, Asia, and the Middle East.
Snapshot
Operations
Products and/or services of PTC Therapeutics
- Duchenne Muscular Dystrophy Therapies: Commercialization of nonsense mutation restoration and corticosteroid treatments for Duchenne muscular dystrophy, generating revenues through global distribution of oral small-molecule formulations designed to slow muscle degeneration in pediatric and adult genetic patients.
- Spinal Muscular Atrophy Treatments: Production and commercialization under joint royalty agreements of oral small-molecule RNA splicing modifiers targeting the SMN2 gene to restore survival motor neuron protein levels in pediatric and adult spinal muscular atrophy.
- Gene Therapy Operations: Development and delivery of recombinant adeno-associated virus gene therapies, including direct micro-infused central nervous system treatments targeting aromatic L-amino acid decarboxylase deficiency in specialized clinical centers across North America and Europe.
- Rare Metabolic Disease Therapies: Clinical development and commercial preparation of oral sepiapterin formulations designed to reduce blood phenylalanine concentration and improve metabolic control in patients diagnosed with phenylketonuria across international regulatory jurisdictions.
- Central Nervous System & Friedreich's Ataxia Pipeline: Development of small-molecule oral therapies targeting oxidative stress, ferroptosis, and neuroinflammation pathways to mitigate central nervous system degeneration and neuromuscular impairment in conditions such as Friedreich's ataxia.
- Huntington's Disease Research: Preclinical and clinical advancement of orally bioavailable pre-mRNA splicing modifier small molecules engineered to selectively reduce mutated huntingtin protein expression in adult and pediatric patients affected by Huntington's disease.
PTC Therapeutics executive team
- Dr. Matthew B. Klein F.A.C.S., M.D., M.S.CEO & Director
- Dr. Allan Steven Jacobson Ph.D.Co-Founder & Independent Director
- Mr. Pierre Gravier M.S.Chief Financial Officer
- Dr. Neil Almstead Ph.D.Chief Technical Operations Officer
- Mr. Eric PauwelsChief Business Officer
- Dr. Lee Scott Golden M.D., Ph.D.Executive VP & Chief Medical Officer
- Ms. Christine Utter CPASenior VP, Chief Accounting Officer & Head of People Services
- Ms. Linda Montella CarterSenior VP & Chief Information Officer
- Mr. Mark Elliott Boulding J.D.Executive VP & Chief Legal Officer
- Ms. Jane BajVice President of Corporate Communications